Patients with multiple sclerosis who were set to switch to a new, costly drug after the government added it to its formulary list last week are being denied it without further explanation, Times of Malta has learnt.
The government had announced that people with MS would be receiving the pill-based medicine, which was promised in the last Budget, by April.
The first dose of Gilenya (fingolimod) must be administered in a hospital setting where the patient’s heart rhythm is monitored for at least six hours. After being given the green light, the patient can continue taking the pill daily from home.
Read the full story in Times of Malta, the e-paper or timesofmalta.com premium here.